Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07040202 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Responses to Dengue and Sepsis

Study acronym: DEN-SEP
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 7 months later Nov 2025 → Jul 2027
See other at-risk trials from Institut Pasteur du Cambodge

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Nov 2025 to Jul 2027 Show 7 more changesShow less
    • Primary endpoints: details revised at 2 of 3 entries
    • Study completion pushed from Dec 2026 to Jul 2027
    • Trial arms changed: 3 → 4
    • Study sites: 3 to 4
    • Eligibility criteria expanded, about 50 words
    • Secondary endpoints revised (9)
    • Study description expanded, about 29 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza, sepsis, or healthy people. The investigators will perform multiple analyses on the blood samples and compare results between dengue patients and those with influenza or sepsis and healthy people.
Trial Details
NCT Number NCT07040202
Lead Sponsor Institut Pasteur du Cambodge
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 Dengue, Sepsis, Influenza
Related terms Dengue, Infections, Influenza, Human, Sepsis
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov